Five things for pharma marketers to know: Tuesday, July 31, 2018

Share this content:

Pfizer lowered its full-year revenue forecast, citing a stronger dollar, on Tuesday morning. However, the drugmaker beat analysts' estimates for its Q2 profit, boosted by arthritis and cholesterol drug sales. (Reuters)

It's been a busy summer for healthcare agency deals. Huntsworth Health's Evoke Group purchased Giant Creative Strategy, Publicis Health acquired Payer Sciences, and UDG Healthcare bought Create NYC -- and that was just in July. With pharma companies finding it harder to differentiate products, agencies are looking to gain scale in complementary services through M&A. (MM&M)

Bayer has struck a deal to sell its prescription dermatology brands to Denmark-based Leo Pharma. The portfolio saw 2017 revenue of $328 million; it includes prescription skin creams to treat acne, fungal skin infections, and rosacea. (Reuters)

The FDA has issued a warning advising doctors against performing vaginal rejuvenation procedures. Marketed as a fix for symptoms in older women, including incontinence and painful sex, the treatments are often unvetted and dangerous, according to the agency. "These products have serious risks and don't have adequate evidence to support their use for these purposes,” FDA Commissioner Scott Gottlieb said in a statement. (CNBC)

Laquinimod has struck out in a Phase II study for Huntington's disease. The once-promising drug has also failed trials for relapsing, remitting, and progressive multiple sclerosis. (Endpoints News)

Share this content:
Scroll down to see the next article